Register entry
Taiho Oncology, Inc.
- Registered sites
- 2
- Drug products
- 0
- Live patents
- 24
- Countries
- 1
- Base
- Japan
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureFinished drug manufacture
Sites
Facilities
2| Site | Location | Operations | FEI |
|---|---|---|---|
| Taiho Pharmaceutical Co., Ltd. | Itano-gunJapan | Analytical testing, Finished drug manufacture | 3010872322 |
| Taiho Pharmaceutical Co., Ltd. | Kodama-gunJapan | Analytical testing, Active ingredient (API) manufacture | 3002646390 |
Exclusivity
Patents
24Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| INQOVI | CEDAZURIDINE; DECITABINE | Oct 2028 |
| INQOVI | CEDAZURIDINE; DECITABINE | Aug 2030 |
| INQOVI | CEDAZURIDINE; DECITABINE | Oct 2040 |
| INQOVI | CEDAZURIDINE; DECITABINE | Feb 2041 |
| LONSURF | TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE | Sept 2029 |
| LONSURF | TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE | Jun 2034 |
| LONSURF | TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE | Sept 2034 |
| LONSURF | TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE | Feb 2037 |
| LYTGOBI | FUTIBATINIB | Feb 2033 |
| LYTGOBI | FUTIBATINIB | Mar 2036 |
| LYTGOBI | FUTIBATINIB | Nov 2039 |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.